Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C

[PR Newswire] – NORTH CHICAGO, Ill., Nov. 16, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an … . . . → Read More: Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting